MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- AUROBINDO PHARMA LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
Aurobindo Pharma Quarterly Results 
(AUBD)
Here are the latest quarterly results of Aurobindo Pharma. For more details, see the Aurobindo Pharma financial fact sheet and Aurobindo Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
Aurobindo Pharma Quarterly Results
| No. of Mths Qtr. Ending |
3
Mar-17* |
3
Jun-17* |
3
Sep-17* |
3
Dec-17* |
3
Mar-18* |
3
Jun-18* |
3
Sep-18* |
3
Dec-18* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 36,416 | 36,788 | 44,359 | 43,361 | 40,491 | 42,503 | 47,514 | 52,697 | |
| Other income | Rs m | 408 | 333 | 103 | 331 | 438 | 437 | 263 | 639 | |
| Turnover | Rs m | 36,824 | 37,120 | 44,462 | 43,692 | 40,929 | 42,940 | 47,777 | 53,335 | |
| Expenses | Rs m | 29,204 | 28,560 | 33,190 | 33,105 | 32,610 | 35,392 | 37,651 | 41,833 | |
| Gross profit | Rs m | 7,215 | 8,228 | 11,169 | 10,258 | 7,884 | 7,111 | 9,594 | 10,613 | |
| Depreciation | Rs m | 1,001 | 1,312 | 1,321 | 1,381 | 1,566 | 1,545 | 1,637 | 1,631 | |
| Interest | Rs m | 143 | 169 | 173 | 189 | 247 | 295 | 354 | 477 | |
| Profit before tax | Rs m | 6,479 | 7,080 | 9,778 | 9,020 | 6,509 | 5,707 | 7,866 | 9,144 | |
| Tax | Rs m | 1,172 | 1,910 | 1,980 | 3,069 | 1,224 | 1,155 | 1,754 | 2,048 | |
| Profit after tax | Rs m | 5,308 | 5,170 | 7,798 | 5,950 | 5,285 | 4,552 | 6,112 | 7,096 | |
| Gross profit margin | % | 19.8 | 22.4 | 25.2 | 23.7 | 19.5 | 16.7 | 20.2 | 20.1 | |
| Effective tax rate | % | 18.1 | 27.0 | 20.2 | 34.0 | 18.8 | 20.2 | 22.3 | 22.4 | |
| Net profit margin | % | 14.6 | 14.1 | 17.6 | 13.7 | 13.1 | 10.7 | 12.9 | 13.5 | |
| Diluted EPS | Rs | 9.1 | 8.8 | 13.3 | 10.2 | 9.0 | 7.8 | 10.4 | 12.1 | |
| Diluted EPS (TTM) | Rs | 39.2 | 38.1 | 41.1 | 41.4 | 41.4 | 40.3 | 37.4 | 39.4 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: Aurobindo Pharma 3QFY19 Result Performance Review
More Pharmaceuticals Company Quarterly Results: PIRAMAL ENTERPRISES NOVARTIS GLENMARK PHARMA SUN PHARMA NATCO PHARMA
Compare AUROBINDO PHARMA With: PIRAMAL ENTERPRISES NOVARTIS GLENMARK PHARMA SUN PHARMA NATCO PHARMA
Compare AUROBINDO PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Modi's Victory Creates Sensex History; Ache Din Ahead?(Podcast)
Throughout the week, one slogan that took over the market and country as a whole was, Ab ki baar phir Modi Sarkar.
Views on news
AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)
Feb 12, 2019 | Updated on Feb 12, 2019For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Dec 19, 2018 | Updated on Dec 19, 2018Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.
AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)
Nov 14, 2018 | Updated on Nov 14, 2018For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)
May 16, 2019Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.
3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)
May 14, 2019As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.
Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)
May 17, 2019A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.
What Makes TVS Srichakra and CCL Products a Cut Above the Rest?(The 5 Minute Wrapup)
May 17, 2019Despite the commodity nature of their businesses, these two stocks have rewarded shareholders well.
The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)
May 14, 2019These companies will help the Sensex more than double from current levels.
More|
| |
AUROBINDO PHARMA SHARE PRICE
May 24, 2019 (Close)
TRACK AUROBINDO PHARMA
- Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AUROBINDO PHARMA
AUROBINDO PHARMA 5-YR ANALYSIS
COMPARE AUROBINDO PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.